No Man

Sign in

Join Free
Post RFQ

Itacitinib

TypeName: Business Offer

Category:

Offer Date:2019/09/04

Country: United States

Summary: Itacitinib is a potent Janus kinase-1 inhibitor under the development of AstraZeneca and Incyte Corporation. Itacitinib can inhibit OCT2-mediated uptake of creatinine as well as MATE1-/MATE2-K-mediated efflux of creatinine. Now it is in a Phase III trial for the treatment of graft-versus-host disease. https://www.bocsci.com/itacitinib-cas-1334298-90-6-item-474483.html

Description:

OfferId: 5440

Name:Alex Brown

Telphone:

Email:[email protected]